Synthetically defined glycoprotein vaccines: current status and future directions
Abstract
Primary examples in vaccine design have shown good levels of
- This article is part of the themed collection: Chemical Biology
Maintenance work is planned from 09:00 BST to 12:00 BST on Saturday 28th September 2024.
During this time the performance of our website may be affected - searches may run slowly, some pages may be temporarily unavailable, and you may be unable to access content. If this happens, please try refreshing your web browser or try waiting two to three minutes before trying again.
We apologise for any inconvenience this might cause and thank you for your patience.
* Corresponding authors
a
Research Center, Novartis Vaccines and Diagnostics, Via Fiorentina 1, 53100 Siena, Italy
E-mail:
Roberto.Adamo@novartis.com
b Department of Chemistry and Applied Biosciences, ETH Zürich, Wolfgang-Pauli-Str. 10, 8093 Zürich, Switzerland
c Departament de Química Analítica i Química Orgànica, Universitat Rovira i Virgili, C/Marcel·lí Domingo s/n, 43007 Tarragona, Spain
d
Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, UK
E-mail:
gb453@cam.ac.uk
e
Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal
E-mail:
gbernardes@fm.ul.pt
Primary examples in vaccine design have shown good levels of
R. Adamo, A. Nilo, B. Castagner, O. Boutureira, F. Berti and G. J. L. Bernardes, Chem. Sci., 2013, 4, 2995 DOI: 10.1039/C3SC50862E
This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.
Read more about how to correctly acknowledge RSC content.
Fetching data from CrossRef.
This may take some time to load.
Loading related content